← United States · All US Insider Profiles

US INSIDER PROFILE · NON-SCORING RESEARCH

TANG CAPITAL MANAGEMENT LLC

10% Owner

Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001232621

Purchase history

Companies traded
3
Purchases · 12M
9
Purchases · 24M
9
Average purchase
$1.7M
Median purchase
$268.9K
Gross purchase value
$15.5M

Companies: Aurinia Pharmaceuticals Inc. | Boundless Bio, Inc. | Fulcrum Therapeutics, Inc.

9 SEC accession(s) · 9 joint-owner event(s). Values are reported Form 4 transaction values in USD.

Qualifying purchase disclosures

PublishedCompanyTickerRoleReported valueSEC source
2026-07-21Boundless Bio, Inc.BOLD10% Owner$11.9KOpen filing
2026-07-20Fulcrum Therapeutics, Inc.FULC10% Owner$594.7KOpen filing
2026-07-16Boundless Bio, Inc.BOLD10% Owner$155.6KOpen filing
2026-07-15Fulcrum Therapeutics, Inc.FULC10% Owner$891.1KOpen filing
2026-07-13Boundless Bio, Inc.BOLD10% Owner$222.1KOpen filing
2026-07-08Boundless Bio, Inc.BOLD10% Owner$141.9KOpen filing
2026-07-02Boundless Bio, Inc.BOLD10% Owner$268.9KOpen filing
2026-06-29Boundless Bio, Inc.BOLD10% Owner$714.8KOpen filing
2026-06-02Aurinia Pharmaceuticals Inc.AUPH10% Owner$12.5MOpen filing

Post-purchase outcomes

Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.

PeriodCompleted eventsPrice coverageHit rateMedian excess returnAverage excess returnWorst excess return
5D1Small Sample11.1% (1/9)100.0% (1/1)+5.5%+5.5%+5.5%
20D1Small Sample11.1% (1/9)100.0% (1/1)+4.2%+4.2%+4.2%
60D1Small Sample11.1% (1/9)100.0% (1/1)+5.3%+5.3%+5.3%
120D0No DataAwaiting maturity————

Research patterns

First purchase in 12M
3/9
Large purchase ≥ $100k
8/9
Cluster buying · 15D
9/9
Buying the dip
0/1

Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.

Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.